Chemistry:MK-7240

From HandWiki
Short description: Humanized monoclonal antibody


MK-7240 (formerly PRA-023) is a humanized monoclonal antibody developed for ulcerative colitis and Crohn's disease.[1][2][3] Before the company was acquired by Merck for $10.8 billion, it was developed by Prometheus Biosciences.[4]

References

  1. ↑ Tubau-Juni, Nuria; Hontecillas, Raquel; Leber, Andrew J; Alva, Sameeksha S; Bassaganya-Riera, Josep (2 November 2023). "Treating Autoimmune Diseases With LANCL2 Therapeutics: A Novel Immunoregulatory Mechanism for Patients With Ulcerative Colitis and Crohn’s Disease". Inflammatory Bowel Diseases. doi:10.1093/ibd/izad258. 
  2. ↑ Feagan, B G; Sands, B; Siegel, C A; Dubinsky, M; Longman, R; Sabinho, J; Laurent, O; Luo, A et al. (30 January 2023). "DOP87 The Anti-TL1A Antibody PRA023 Demonstrated Proof-of-Concept in Crohn’s Disease: Phase 2a APOLLO-CD Study Results". Journal of Crohn's and Colitis 17 (Supplement_1): i162–i164. doi:10.1093/ecco-jcc/jjac190.0127. 
  3. ↑ Sands, B; Peyrin-Biroulet, L; Danese, S; Rubin, D T; Vermeire, S; Laurent, O; Luo, A; Nguyen, D et al. (30 January 2023). "OP40 PRA023 Demonstrated Efficacy and Favorable Safety as Induction Therapy for Moderately to Severely Active UC: Phase 2 ARTEMIS-UC Study Results". Journal of Crohn's and Colitis 17 (Supplement_1): i56–i59. doi:10.1093/ecco-jcc/jjac190.0040. 
  4. ↑ "Merck Closes Prometheus Acquisition". San Diego Business Journal. 24 June 2023. https://www.sdbj.com/life-sciences/pharmaceuticals/merck-closes-prometheus-acquisition/. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:MK-7240&oldid=3320613"